/ Pharmacology reference

Peptide half-life, side by side.

Half-life is the time it takes for a compound to fall to half its concentration in the body. It ranges from a couple of minutes for some peptides to about a week for the long-acting GLP-1 compounds. The table covers every compound in the library. Sort it by name, category, or half-life, and filter by class. Educational reference only, not medical advice, a schedule, or a dosing recommendation.

43 compounds · sorted by half-life (ascending)

Reference
ARA-290CibinetideHealing / RecoveryShort; ~2 min (IV), ~10-20 min terminal (subcutaneous)Verified
VIPVasoactive Intestinal Peptide · AviptadilCognitive / LongevityVery short in plasma (~1-2 min); rapidly degraded by peptidasesVerified
KisspeptinKisspeptin-10 · Kisspeptin-54Sexual / HormonalKisspeptin-10 ~4 min; kisspeptin-54 ~27.6 min, intravenousVerified
SemaxCognitive / LongevityMinutes in plasma (~2-5 min); intranasal or subcutaneousVerified
GonadorelinGnRH · FactrelSexual / Hormonal~2-10 min (IV distribution); terminal ~10-40 minVerified
BPC-157Body Protection Compound · PL 14736Healing / RecoveryShort; ~15 min (rat, IV); no human PK publishedVerified
DSIPDelta Sleep-Inducing PeptideCognitive / LongevityShort, minutes in plasma (~7-15 min reported); IV or subcutaneousVerified
SermorelinGeref · GHRH 1-29Growth Hormone~10-20 min (reported ~12 min), subcutaneousVerified
GHRP-2PralmorelinGrowth HormoneShort; ~30 min (approximate), subcutaneousVerified
GHRP-6Growth HormoneShort; ~20-30 min (some studies report up to ~2.5 h), subcutaneousVerified
TesamorelinEgriftaGLP-1 / Metabolic~26-38 min, subcutaneousVerified
MOTS-cMOTScGLP-1 / MetabolicNot well characterized in humans; preclinical estimates short (~45 min to a few hours)Verified
HexarelinGrowth Hormone~55 min (human, subcutaneous); ~76 min IV in animal studiesVerified
AOD-9604AOD9604 · hGH 176-191GLP-1 / MetabolicNot well characterized in humans; reported short (minutes to ~1 h)Verified
Melanotan IAfamelanotide · ScenesseSexual / HormonalIntrinsic peptide half-life short (under ~1 h); the approved implant (Scenesse) is a bioresorbable subcutaneous depot releasing over about 2 daysVerified
Melanotan IIMT-2 · MT2Sexual / Hormonal~1 h, subcutaneous (limited human PK)Verified
IpamorelinGrowth Hormone~2 h, subcutaneousVerified
SS-31ElamipretideCognitive / Longevity~2 h, subcutaneous or IVVerified
PT-141Bremelanotide · VyleesiSexual / Hormonal~2.7 h terminal (range 1.9-4.0 h), subcutaneousVerified
Thymosin Alpha-1Tα1 · ZadaxinHealing / Recovery~2-3 h, subcutaneousVerified
5-Amino-1MQ5A1MQCognitive / Longevity~3.8 h IV and ~6.9 h oral in rat; no published human PKVerified
NAD+Nicotinamide adenine dinucleotideCognitive / LongevityIntracellular turnover ~1-4 h (compartment-dependent); a single plasma half-life is not well definedVerified
LiraglutideSaxenda · VictozaGLP-1 / Metabolic~13 h, subcutaneousVerified
MK-677Ibutamoren · NutrobalGrowth Hormone~24 h, oralVerified
Pentosan PolysulfatePPS · ElmironHealing / Recovery~20-27 h (plasma radioactivity), oralVerified
IGF-1 LR3Long R3 IGF-1Cognitive / Longevity~20-30 h reported (subcutaneous); some sources cite longerVerified
HCGHuman Chorionic Gonadotropin · NovarelSexual / HormonalBiphasic; terminal ~24-36 h, intramuscular or subcutaneousVerified
TirzepatideMounjaro · ZepboundGLP-1 / Metabolic~5 days (~120 h), subcutaneousVerified
RetatrutideReta · Triple-GGLP-1 / Metabolic~6 days, subcutaneousVerified
CagrilintideCagri · NN9838GLP-1 / Metabolic~7 days (~6-8 days), subcutaneousVerified
SemaglutideOzempic · WegovyGLP-1 / Metabolic~1 week (~168 h), subcutaneousVerified
SurvodutideBI 456906GLP-1 / Metabolic~6-7 days, subcutaneousVerified
CJC-1295with DAC · mod GRF 1-29Growth HormoneWith DAC ~6-8 days; without DAC (mod GRF 1-29) ~30 min, subcutaneousVerified
TesofensineNS2330GLP-1 / Metabolic~9 days (~220 h), oralVerified
DihexaPNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amideCognitive / LongevityNot established in humans; engineered for metabolic stability relative to native angiotensin IV (no published human PK)Verified
EpithalonEpitalon · AEDGCognitive / LongevityNot established (no published human PK); expected short for a linear tetrapeptideEmerging
GHK-CuCopper Peptide · Copper tripeptide-1Healing / RecoverySystemic half-life not well characterized; typically studied topicallyVerified
KLOWGHK-Cu + TB-500 + BPC-157 + KPVHealing / RecoveryVaries by component (see individual profiles)Emerging
KPVLysine-Proline-ValineHealing / RecoveryNot well characterized in humans (preclinical peptide)Verified
LL-37Cathelicidin · hCAP18Healing / RecoveryNot well characterized in humans; short (endogenous, protease-sensitive peptide)Verified
MGFPEG-MGF · Mechano Growth FactorGrowth HormoneNative peptide very short (minutes); pegylation (PEG-MGF) extends stability. No established human PKVerified
SelankCognitive / LongevityA few minutes in plasma (rapidly degraded); intranasal or IVVerified
TB-500Thymosin Beta-4 fragment · TB4Healing / RecoveryReported in hours; precise human PK sparse, subcutaneousVerified

Half-life is an educational pharmacology figure drawn from public sources. It describes how long a compound persists, not a schedule, a frequency, or a dosing instruction. Values marked emerging are not corroborated by an authoritative public source.

01

What half-life describes, and what it does not

Half-life is a property of the molecule and the body, measured in controlled studies. A short half-life means the compound clears quickly; a long one means it lingers. It is a useful way to understand how different compounds behave, and a poor way to invent a plan. Half-life is not a frequency, an interval, or an amount, and nothing on this page should be read as one.

02

Why the numbers vary so much

Small linear peptides are often degraded by enzymes within minutes. Engineering changes that. Attaching a fatty-acid chain or a group that binds albumin, or adding a stabilizing modification, can stretch a half-life from minutes to days. That is why two compounds in the same class can sit at opposite ends of the table. Where a figure is not established in humans, the reference column marks it as emerging rather than implying a precision that does not exist.

03

Read the full profile

Each compound name links to its full reference page: identity, mechanism class, storage and handling, and the public sources behind it. Start from the compound library to search or filter the full set.

43 compounds. Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.